Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PSIP1
REST API REST API
Homo sapiens
PSIP1 is differentially expressed in 390 experiments: 167 organism parts: liver, ovary, ... (165 more);, 252 disease states: normal, control, ... (250 more);, 126 cell types 473 cell lines 46 compound treatments and 85 other conditions.
Synonyms p52, p75, LEDGF, PSIP2
Orthologs Psip1 (Rattus norvegicus)   PSIP1 (Bos taurus)   Psip1 (Mus musculus)   PSIP1 (Gallus gallus)   CG7946 (Drosophila melanogaster)   psip1 (Danio rerio)   psip1 (Xenopus laevis)   PSIP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, nuclear periphery, response to oxidative stress, DNA binding, protein binding, regulation of transcription, DNA-dependent, nuclear heterochromatin, positive regulation of transcription from RNA polymerase II promoter, nucleus, chromatin binding, nucleoplasm, response to heat, viral reproduction, interspecies interaction between organisms, activating transcription factor binding, provirus integration, nuclear mRNA 5'-splice site recognition, initiation of viral infection, RNA polymerase II transcription coactivator activity, transcriptionally active chromatin, supercoiled DNA binding
InterPro Term PWWP, Treacle-like_TCS, LEDGF
UniProt Accession Q8N4N4, O75475
Search EB-eye ENSG00000164985
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7224, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
H1437
2
E-GEOD-16194, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
467 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, ... (60 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998, E-GEOD-96
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
3
E-AFMX-5, E-MEXP-1600, E-GEOD-6740, E-TABM-145, E-GEOD-16190 ... (5 experiments)
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
120 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (77 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-37, E-TABM-26, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295, E-GEOD-20602
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
246 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-TABM-782, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-GEOD-3720, E-TABM-868, E-MEXP-1958
none
8
9
E-GEOD-5824, E-TABM-868, E-TABM-782, E-MEXP-1958, E-MEXP-1601, ... (17 experiments)
glutamine
1
E-MEXP-941
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
placebo
1
E-MEXP-1327
interferon-gamma
1
E-GEOD-1925
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-19246, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-1045, E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-TABM-440, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (42 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (9 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-22541, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, ... (10 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.371 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM